Publication: Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.
No Thumbnail Available
Identifiers
Date
2022-08-03
Authors
Ángel Calleja, Miguel
Navarro, Andrés
Serratosa, José María
Toledo, Manuel
Villanueva, Vicente
Subías Labazuy, Silvia
Gil, Alicia
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
To determine the economically justifiable price (EJP) of cenobamate to become a cost-effective alternative compared with third-generation anti-seizure medications in the treatment of focal-onset seizures (FOS) in adult patients with drug-resistant epilepsy (DRE) in Spain. Cost-effectiveness analysis compared cenobamate with brivaracetam, perampanel, eslicarbazepine acetate, and lacosamide. Markov model simulation of treatment pathway over a 60-year time horizon is presented. We determined the effectiveness and quality-adjusted life-years (QALYs) of health status and disutilities associated with treatment-related adverse events. Acquisition costs and use of medical resources were obtained from published literature and expert opinion. Base-case of cenobamate's EJP calculated applying a willingness-to-pay (WTP) threshold of €21,000/QALY. Analyses were performed at different thresholds, including dominant price scenario. Result robustness was assessed through sensitivity analyses. Base-case shows that cenobamate's daily EJP of €7.30 is cost-effective for a threshold of €21,000/QALY. At a daily price of €5.45, cenobamate becomes dominant over all treatment alternatives producing cost-savings for the national health system (NHS). Sensitivity analyses supported the robustness of base-case findings. Treatment with cenobamate produces incremental clinical benefit over third-generation ASMs, and at the base-case, EJP could represent a cost-effective option for the adjunctive treatment of FOS in adult patients with DRE in Spain.
Description
MeSH Terms
Adult
Carbamates
Chlorophenols
Cost-Benefit Analysis
Epilepsy
Humans
Lacosamide
Quality-Adjusted Life Years
Spain
Tetrazoles
Carbamates
Chlorophenols
Cost-Benefit Analysis
Epilepsy
Humans
Lacosamide
Quality-Adjusted Life Years
Spain
Tetrazoles
DeCS Terms
CIE Terms
Keywords
Anti-seizure medications, Spain, cenobamate, cost-effectiveness, drug-resistant epilepsy, economically justifiable price